

Lupin acquires brands from AFDIL

07 April 2022 | News

The acquisition will strengthen Lupin's India Formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products



Lupin announced the completion of a portfolio of brands from Anglo-French Drugs & Industries Limited (AFDIL) and its Associates.

The acquisition will strengthen Lupin's India Formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products. The acquisition of the AFDIL brands takes Lupin further in shaping its portfolio to emerge as a leading pharmaceutical company in India.

"With this portfolio, Lupin will have a stronger market presence, providing healthcare professionals and patients with a more meaningful and comprehensive product offering," said Nilesh Gupta, MD, Lupin.

"We are confident in Lupin's ability to enhance the value of our portfolio of brands," said Abhay Kanoria, CMD, AFDIL.

Shailesh Gadre, Founder, GCV Life was the exclusive advisor for the transaction.